ALLMedicine™ Leukemias Center
Research & Reviews 2,319 results
https://clinicaltrials.gov/ct2/show/NCT02390752
Feb 3rd, 2023 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...
https://clinicaltrials.gov/ct2/show/NCT05237986
Feb 3rd, 2023 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...
https://doi.org/10.1097/MPH.0000000000002589
Journal of Pediatric Hematology/oncology; Bokun J, Popović-Vuković M et. al.
Feb 3rd, 2023 - Radiotherapy plays an important role in the multimodal treatment of childhood cancer. Our objective was to provide an analysis of pediatric oncology patients treated with radiotherapy in a national referral institution in Serbia. A retrospective c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885707
Molecular Cancer; Maalej KM, Merhi M et. al.
Feb 1st, 2023 - In the last decade, Chimeric Antigen Receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach to fight cancers. This approach consists of genetically engineered immune cells expressing a surface receptor, called CAR, tha...
https://doi.org/10.1097/MPH.0000000000002625
Journal of Pediatric Hematology/oncology; Kourti M, Papakonstantinou E et. al.
Jan 31st, 2023 - Aim of this study was to evaluate the long-term therapeutic outcome and treatment-related complications in Hodgkin disease. We reviewed the medical records of 93 patients diagnosed with classic Hodgkin lymphoma, treated, and followed-up during the...
Guidelines 2 results
https://doi.org/10.6004/jnccn.2017.0165
Journal of the National Comprehensive Cancer Network : JN... Wierda WG, Byrd JC et. al.
Nov 10th, 2017 - Hairy cell leukemia (HCL) is a rare type of indolent B-cell leukemia, characterized by symptoms of fatigue and weakness, organomegaly, pancytopenia, and recurrent opportunistic infections. Classic HCL should be considered a distinct clinical entit...
https://doi.org/10.6004/jnccn.2017.0116
Journal of the National Comprehensive Cancer Network : JN... O'Donnell MR, Tallman MS et. al.
Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...
Drugs 422 results see all →
Clinicaltrials.gov 237 results
https://clinicaltrials.gov/ct2/show/NCT02390752
Feb 3rd, 2023 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...
https://clinicaltrials.gov/ct2/show/NCT05237986
Feb 3rd, 2023 - Background: Chimeric antigen receptor (CAR) T-cell immunotherapy has rapidly emerged as a successful and breakthrough treatment in pediatric and adult hematologic malignancies. However, significant toxicities can complicate the therapeutic success...
https://clinicaltrials.gov/ct2/show/NCT04726241
Jan 31st, 2023 - PRIMARY OBJECTIVES: I. To utilize clinical and biological characteristics of acute leukemias to screen for patient eligibility for available phase I/II Pediatric Acute Leukemia (PedAL) sub-trials. II. To maintain a longitudinal and comprehensive r...
https://clinicaltrials.gov/ct2/show/NCT03289910
Jan 30th, 2023 - PRIMARY OBJECTIVE: I. To estimate and compare the complete response/complete response with incomplete recovery (CR/CRi) rate of induction therapy with topotecan hydrochloride (topotecan)/carboplatin (T/C) with or without veliparib (V) in myeloprol...
https://clinicaltrials.gov/ct2/show/NCT05521087
Jan 30th, 2023 - The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2Ds) of JNJ-75276617 in combination with a conventional chemotherapy backbone in pediatric and young adult participants with relapsed/refractory acute leukemia harboring ...
News 605 results
https://www.mdedge.com/hematology-oncology/article/260749/mixed-topics/mastocytosis-rare-underdiagnosed-potentially-fatal
Helen Leask, PhD
Jan 24th, 2023 - Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it. This call to action was issued late in 2022 by Stanford (Calif.
https://www.onclive.com/view/first-patient-dosed-with-menin-inhibitor-bmf-219-in-covalent-101-trial-in-cll
Nov 21st, 2022 - The first patient in the chronic lymphocytic leukemia (CLL) cohort has been dosed in the phase 1 COVALENT-101 trial (NCT05153330), which is evaluating the first-in-class covalent menin inhibitor BMF-219, in patients with relapsed/refractory acute ...
https://www.onclive.com/view/treatments-for-mcl-continue-to-progress
Nov 18th, 2022 - As research and treatment options for patients with mantle cell lymphoma (MCL) continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step...
https://www.onclive.com/view/car-therapy-era-moves-forward-with-much-excitement-lingering-questions
Nov 16th, 2022 - CAR T-cell therapies have generated considerable enthusiasm in the oncology community since the first FDA approval in 2017. From a clinical standpoint, these therapies have significantly improved outcomes in disease settings where the outlook for ...
https://www.onclive.com/view/innovations-are-poised-to-lead-mpn-mds-treatment-landscape-in-a-positive-direction
Nov 9th, 2022 - A full day of programming on hematologic malignancies will kick off the 40th Annual Chemotherapy Foundation Symposium. Included in the lineup highlighting advances in multiple myeloma, leukemias, lymphomas, and other issues across malignancies, a ...